ARTICLE | Company News

Boehringer, ViraTherapeutics in oncolytic virus deal

September 28, 2016 7:00 AM UTC

Boehringer Ingelheim GmbH (Ingelheim, Germany) partnered with oncolytic virus play ViraTherapeutics GmbH (Innsbruck, Austria) to jointly develop ViraTherapeutics' oncolytic virus therapy platform and its lead candidate, VSV-GP.

Boehringer also gained an option to acquire ViraTherapeutics after Phase I testing of VSV-GP is complete. The companies said the deal has a potential value of EUR 210 million ($235.8 million), but did not provide details and did not respond to inquiries. ...